KG&L Capital Management LLC Has $2.62 Million Stake in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

KG&L Capital Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,287 shares of the company’s stock after buying an additional 1,114 shares during the quarter. Johnson & Johnson accounts for about 2.4% of KG&L Capital Management LLC’s portfolio, making the stock its 7th biggest holding. KG&L Capital Management LLC’s holdings in Johnson & Johnson were worth $2,624,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Zions Bancorporation N.A. boosted its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after acquiring an additional 73 shares during the period. Vishria Bird Financial Group LLC boosted its stake in shares of Johnson & Johnson by 3.0% during the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after acquiring an additional 80 shares during the period. Deane Retirement Strategies Inc. boosted its stake in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Deane Retirement Strategies Inc. now owns 12,379 shares of the company’s stock worth $1,724,000 after acquiring an additional 85 shares during the period. Evanson Asset Management LLC boosted its stake in shares of Johnson & Johnson by 0.5% during the 2nd quarter. Evanson Asset Management LLC now owns 17,870 shares of the company’s stock worth $2,489,000 after acquiring an additional 85 shares during the period. Finally, Gilman Hill Asset Management LLC boosted its stake in shares of Johnson & Johnson by 1.1% during the 2nd quarter. Gilman Hill Asset Management LLC now owns 8,137 shares of the company’s stock worth $1,133,000 after acquiring an additional 85 shares during the period. Institutional investors and hedge funds own 72.01% of the company’s stock.

Several research analysts have recently commented on the company. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a research note on Thursday, July 18th. Morgan Stanley reiterated an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Friday. Credit Suisse Group set a $156.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Finally, Barclays assumed coverage on Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 target price for the company. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $151.00.

Shares of NYSE JNJ opened at $131.33 on Friday. The company has a market capitalization of $341.03 billion, a P/E ratio of 14.85, a P/E/G ratio of 2.18 and a beta of 0.69. The stock has a 50 day moving average of $129.92 and a 200-day moving average of $134.97. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period last year, the firm posted $2.10 EPS. Analysts predict that Johnson & Johnson will post 8.59 EPS for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Risk Tolerance and Your Investment Decisions

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CSX  Shares Gap Up  on Strong Earnings
CSX Shares Gap Up on Strong Earnings
Central Pacific Financial Corp.  Short Interest Update
Central Pacific Financial Corp. Short Interest Update
Short Interest in EPAM Systems Inc  Decreases By 8.8%
Short Interest in EPAM Systems Inc Decreases By 8.8%
DXC Technology Co  Short Interest Down 8.3% in September
DXC Technology Co Short Interest Down 8.3% in September
Unify   Trading 5.9% Lower  This Week
Unify Trading 5.9% Lower This Week
Arcblock Price Reaches $0.15
Arcblock Price Reaches $0.15


© 2006-2019 Ticker Report